• Explore /
  • Poster
  • / Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).

Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).

Abstract Poster

Authors

Giorgio Scagliotti

Giorgio V. Scagliotti

Department of Oncology, University of Turin, S. Luigi Hospital, Torino, Italy

Giorgio V. Scagliotti , Rabab M. Gaafar , Anna K. Nowak , Jan P. Van Meerbeeck , Nicholas J. Vogelzang , Ute von Wangenheim , Arsene-Bienvenu Loembe , Nassim Morsli , Derek Velema , Sanjay Popat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Mesothelioma

Clinical Trial Registration Number

NCT01907100

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS8574)

DOI

10.1200/JCO.2016.34.15_suppl.TPS8574

Abstract #

TPS8574

Poster Bd #

200a

Abstract Disclosures

Similar Posters

First Author: Giorgio V. Scagliotti

First Author: Ankit Madan

First Author: Nasser H. Hanna

First Author: Simon J. Crabb